Bacher, Ulrike

[["dc.bibliographiccitation.firstpage","5512"],["dc.bibliographiccitation.issue","22"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Krekeler, Carolin"],["dc.contributor.author","Reitnauer, Lea"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Khandanpour, Cyrus"],["dc.contributor.author","Steger, Leander"],["dc.contributor.author","Boeckel, Göran Ramin"],["dc.contributor.author","Klosner, Justine"],["dc.contributor.author","Tepasse, Phil-Robin"],["dc.contributor.author","Kemper, Marcel"],["dc.contributor.author","Hennies, Marc Tim"],["dc.contributor.author","Shumilov, Evgenii"],["dc.date.accessioned","2022-12-01T08:31:37Z"],["dc.date.available","2022-12-01T08:31:37Z"],["dc.date.issued","2022"],["dc.description.abstract","Background: Two-dose COVID-19 vaccination often results in poor humoral response rates in patients with hematologic malignancies (HMs); yet responses to COVID-19 booster vaccines and the risk of COVID-19 infection post-booster are mostly uncertain. Methods: We included 200 outpatients with HMs and predominantly lymphoid neoplasms (96%, 191/200) in our academic center and reported on the humoral responses, which were assessed by measurement of anti-spike IgG antibodies in peripheral blood as early as 14 days after mRNA-based prime-boost vaccination, as well as factors hampering booster efficacy. Previous basic (double) immunization was applied according to the local recommendations with mRNA- and/or vector-based vaccines. We also report on post-booster COVID-19 breakthrough infections that emerged in the Omicron era and the prophylaxis strategies that were applied to poor and non-responders to booster vaccines. Results: A total of 55% (110/200) of the patients achieved seroconversion (i.e., anti-spike protein IgG antibody titer > 100 AU/mL assessed in median 48 days after prime-boost vaccination) after prime-boost vaccination. Multivariable analyses revealed age, lymphocytopenia, ongoing treatment and prior anti-CD20 B-cell depletion to be independent predictors for booster failure. With each month between anti-CD20-mediated B-cell depletion and booster vaccination, the probability of seroconversion increased by approximately 4% (p < 0.001) and serum–antibody titer (S-AbT) levels increased by 90 AU/mL (p = 0.011). Notably, obinutuzumab treatment was associated with an 85% lower probability for seroconversion after prime-boost vaccination compared to rituximab (p = 0.002). Of poor or non-responders to prime-boost vaccination, 41% (47/114) underwent a second booster and 73% (83/114) underwent passive immunization. COVID-19 breakthrough infections were observed in 15% (29/200) of patients after prime-boost vaccination with predominantly mild courses (93%). Next to seroconversion, passive immunization was associated with a significantly lower risk of COVID-19 breakthrough infections after booster, even in vaccine non-responders (all p < 0.05). In a small proportion of analyzed patients with myeloid neoplasms (9/200), the seroconversion rate was higher compared to those with lymphoid ones (78% vs. 54%, accordingly), while the incidence rate of COVID-19 breakthrough infections was similar (22% vs. 14%, respectively). Following the low frequency of myeloid neoplasms in this study, the results may not be automatically applied to a larger cohort. Conclusions: Patients with HMs are at a high risk of COVID-19 booster vaccine failure; yet COVID-19 breakthrough infections after prime-boost vaccination are predominantly mild. Booster failure can likely be overcome by passive immunization, thereby providing immune protection against COVID-19 and attenuating the severity of COVID-19 courses. Further sophistication of clinical algorithms for preventing post-vaccination COVID-19 breakthrough infections is urgently needed."],["dc.identifier.doi","10.3390/cancers14225512"],["dc.identifier.pii","cancers14225512"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118221"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","2072-6694"],["dc.title","Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2476"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Leukemia & Lymphoma"],["dc.bibliographiccitation.lastpage","2480"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Hellige, Niels"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Binder, Mascha"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2020-12-10T18:43:56Z"],["dc.date.available","2020-12-10T18:43:56Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.3109/10428194.2016.1151510"],["dc.identifier.eissn","1029-2403"],["dc.identifier.issn","1042-8194"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78273"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","64"],["dc.bibliographiccitation.journal","Critical Reviews in Oncology/Hematology"],["dc.bibliographiccitation.lastpage","79"],["dc.bibliographiccitation.volume","126"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Flach, Johanna"],["dc.contributor.author","Pabst, Thomas"],["dc.contributor.author","Fiedler, Martin"],["dc.contributor.author","Angelillo-Scherrer, Anne"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Joncourt, Raphael"],["dc.contributor.author","Kohlmann, Alexander"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2020-12-10T14:23:20Z"],["dc.date.available","2020-12-10T14:23:20Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.critrevonc.2018.03.020"],["dc.identifier.issn","1040-8428"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71901"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Cancer Education"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Vehling-Kaiser, Ursula"],["dc.contributor.author","Damnali, Gamze"],["dc.contributor.author","Schulz, Xenia"],["dc.contributor.author","Kaiser, Ulrich"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Kaiser, Florian"],["dc.date.accessioned","2021-06-01T10:49:21Z"],["dc.date.available","2021-06-01T10:49:21Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s13187-020-01794-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86258"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1543-0154"],["dc.relation.issn","0885-8195"],["dc.title","Oral and Subcutaneous Anticancer Therapy Training Course for Non-physician Healthcare Professionals: a Survey Evaluating the Relevance of its Content and its Implications in the Practice of Cancer Care"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","276"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Biology of Blood and Marrow Transplantation"],["dc.bibliographiccitation.lastpage","281"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Oyekunle, Anthony"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Kostrewa, Philippe"],["dc.contributor.author","Burchert, Andreas"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Wuchter, Patrick"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Kröger, Nicolaus"],["dc.date.accessioned","2020-12-10T14:22:34Z"],["dc.date.available","2020-12-10T14:22:34Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.bbmt.2017.10.008"],["dc.identifier.issn","1083-8791"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71656"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","766"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Current Oncology"],["dc.bibliographiccitation.lastpage","776"],["dc.bibliographiccitation.volume","29"],["dc.contributor.affiliation","Shumilov, Evgenii; 1Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; Evgenii.Shumilov@ukmuenster.de (E.S.); Myriam.Legros@insel.ch (M.L.); NaomiAzur.Porret@insel.ch (N.P.)"],["dc.contributor.affiliation","Mazzeo, Paolo; 3Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37075 Göttingen, Germany; paolo.Mazzeo@med.uni-goettingen.de (P.M.); detlef.haase@med.uni-goettingen.de (D.H.)"],["dc.contributor.affiliation","Zinkernagel, Martin S.; 4Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; martin.zinkernagel@insel.ch"],["dc.contributor.affiliation","Legros, Myriam; 1Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; Evgenii.Shumilov@ukmuenster.de (E.S.); Myriam.Legros@insel.ch (M.L.); NaomiAzur.Porret@insel.ch (N.P.)"],["dc.contributor.affiliation","Porret, Naomi; 1Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; Evgenii.Shumilov@ukmuenster.de (E.S.); Myriam.Legros@insel.ch (M.L.); NaomiAzur.Porret@insel.ch (N.P.)"],["dc.contributor.affiliation","Romagna, Lorenz; 5Department of Medical Oncology, Inselspital, Bern University Hospital, 3012 Bern, Switzerland; lorenz.romagna@insel.ch (L.R.); Urban.Novak@insel.ch (U.N.); Thomas.Pabst@insel.ch (T.P.)"],["dc.contributor.affiliation","Haase, Detlef; 3Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37075 Göttingen, Germany; paolo.Mazzeo@med.uni-goettingen.de (P.M.); detlef.haase@med.uni-goettingen.de (D.H.)"],["dc.contributor.affiliation","Lenz, Georg; 2Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, 48149 Münster, Germany; Georg.Lenz@ukmuenster.de"],["dc.contributor.affiliation","Novak, Urban; 5Department of Medical Oncology, Inselspital, Bern University Hospital, 3012 Bern, Switzerland; lorenz.romagna@insel.ch (L.R.); Urban.Novak@insel.ch (U.N.); Thomas.Pabst@insel.ch (T.P.)"],["dc.contributor.affiliation","Banz, Yara; 6Institute of Pathology, University of Bern, 3012 Bern, Switzerland; yara.banz@pathology.unibe.ch"],["dc.contributor.affiliation","Pabst, Thomas; 5Department of Medical Oncology, Inselspital, Bern University Hospital, 3012 Bern, Switzerland; lorenz.romagna@insel.ch (L.R.); Urban.Novak@insel.ch (U.N.); Thomas.Pabst@insel.ch (T.P.)"],["dc.contributor.affiliation","Bacher, Ulrike; 1Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; Evgenii.Shumilov@ukmuenster.de (E.S.); Myriam.Legros@insel.ch (M.L.); NaomiAzur.Porret@insel.ch (N.P.)"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Mazzeo, Paolo"],["dc.contributor.author","Zinkernagel, Martin S."],["dc.contributor.author","Legros, Myriam"],["dc.contributor.author","Porret, Naomi"],["dc.contributor.author","Romagna, Lorenz"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Lenz, Georg"],["dc.contributor.author","Novak, Urban"],["dc.contributor.author","Banz, Yara"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Pabst, Thomas"],["dc.date.accessioned","2022-04-01T10:03:17Z"],["dc.date.available","2022-04-01T10:03:17Z"],["dc.date.issued","2022"],["dc.date.updated","2022-09-03T17:14:09Z"],["dc.description.abstract","Background: Intraocular lymphoma (IOL) presents a real challenge in daily diagnostics. Cyto- and/or histopathology of vitreous body represent the diagnostic cornerstones. Yet, false negative results remain common. Therefore, we analyzed the diagnostic significance of flow cytometry (FC) within the workup algorithm of IOL and compared its sensitivity with the results obtained from routine cytopathology and molecular genetics; Methods: Seven patients undergoing vitrectomy due to suspected IOL were investigated by FC and parallel cytopathology and, if available, digital droplet PCR (ddPCR) for MYD88 L265P; Results: Four out of seven patients were finally diagnosed with IOL. Among the IOL patients, cytopathology confirmed the presence of lymphoma cells in only two cases. In contrast, FC was positive for IOL in all four cases, and FC additionally confirmed the lack of IOL in the remaining patients. In IOL patients diagnosed by FC and with available ddPCR, the diagnosis of IOL was confirmed by the presence of the MYD88 L265P mutation in all three patients; Conclusions: The combination with FC was superior to cytopathology alone in the diagnostic work-up of IOL, and it showed an excellent correlation with ddPCR results. A comprehensive diagnostic panel consisting of cytopathology, FC and molecular genetics should be considered for the work-up of suspected IOL."],["dc.identifier.doi","10.3390/curroncol29020065"],["dc.identifier.pii","curroncol29020065"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/106131"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1718-7729"],["dc.rights","CC BY 4.0"],["dc.title","Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","7"],["dc.bibliographiccitation.journal","Experimental Hematology"],["dc.bibliographiccitation.lastpage","14.e3"],["dc.bibliographiccitation.volume","88"],["dc.contributor.author","Pabst, Thomas"],["dc.contributor.author","Joncourt, Raphael"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Heini, Alexander"],["dc.contributor.author","Wiedemann, Gertrud"],["dc.contributor.author","Legros, Myriam"],["dc.contributor.author","Seipel, Katja"],["dc.contributor.author","Schild, Christof"],["dc.contributor.author","Jalowiec, Katarzyna"],["dc.contributor.author","Mansouri Taleghani, Behrouz"],["dc.contributor.author","Fux, Michaela"],["dc.contributor.author","Novak, Urban"],["dc.contributor.author","Porret, Naomi"],["dc.contributor.author","Zeerleder, Sacha"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2021-04-14T08:24:36Z"],["dc.date.available","2021-04-14T08:24:36Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.exphem.2020.07.003"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81349"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0301-472X"],["dc.title","Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","268"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Genes, Chromosomes and Cancer"],["dc.bibliographiccitation.lastpage","274"],["dc.bibliographiccitation.volume","59"],["dc.contributor.author","Flach, Johanna"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Joncourt, Raphael"],["dc.contributor.author","Porret, Naomi"],["dc.contributor.author","Tchinda, Joëlle"],["dc.contributor.author","Legros, Myriam"],["dc.contributor.author","Scarpelli, Ilaria"],["dc.contributor.author","Hewer, Ekkehard"],["dc.contributor.author","Novak, Urban"],["dc.contributor.author","Schoumans, Jacqueline"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Pabst, Thomas"],["dc.date.accessioned","2020-12-10T14:06:32Z"],["dc.date.available","2020-12-10T14:06:32Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/gcc.v59.4"],["dc.identifier.eissn","1098-2264"],["dc.identifier.issn","1045-2257"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69936"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Detection of rare reciprocal RUNX1 rearrangements by next‐generation sequencing in acute myeloid leukemia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","102977"],["dc.bibliographiccitation.journal","Critical Reviews in Oncology/Hematology"],["dc.bibliographiccitation.volume","151"],["dc.contributor.author","Flach, Johanna"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Joncourt, Raphael"],["dc.contributor.author","Porret, Naomi"],["dc.contributor.author","Novak, Urban"],["dc.contributor.author","Pabst, Thomas"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2021-04-14T08:26:02Z"],["dc.date.available","2021-04-14T08:26:02Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.critrevonc.2020.102977"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81810"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","1040-8428"],["dc.title","Current concepts and future directions for hemato-oncologic diagnostics"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2588"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Leukemia & Lymphoma"],["dc.bibliographiccitation.lastpage","2590"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Flach, Johanna"],["dc.contributor.author","Joncourt, Raphael"],["dc.contributor.author","Porret, Naomi"],["dc.contributor.author","Wiedemann, Gertrud"],["dc.contributor.author","Novak, Urban"],["dc.contributor.author","Gfeller, Eva"],["dc.contributor.author","Jeker, Barbara"],["dc.contributor.author","Amstutz, Ursula"],["dc.contributor.author","Pabst, Thomas"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2020-12-10T18:14:59Z"],["dc.date.available","2020-12-10T18:14:59Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1080/10428194.2019.1585838"],["dc.identifier.eissn","1029-2403"],["dc.identifier.issn","1042-8194"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74693"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]